Format

Send to

Choose Destination
Med Sci (Paris). 2019 Nov;35 Hors série n° 2:7-10. doi: 10.1051/medsci/2019188. Epub 2019 Dec 20.

[Cell therapy in muscular disorders: the future lies in comparisons of progenitors].

[Article in French; Abstract available in French from the publisher]

Author information

1
Sorbonne Université, Inserm UMRS 974, AIM, CNRS, Centre de Recherche en Myologie, Hôpital Pitié Salpêtrière, Faculté de Médecine, 105 boulevard de l'Hôpital, 75013 Paris, France.
2
AFM-Téléthon, 1 rue de l'Internationale, 91000 Évry, France.

Abstract

in English, French

Cell therapy approaches dedicated to the treatment of dystrophinopathies and involving essentially myoblasts and mesoangioblasts have produced mitigated clinical results. If several types of alternative progenitors have been developed, no standardized comparison has been carried out yet to investigate their regenerative efficacy in vivo, at least at a local level. A comparative study has therefore been designed recently aiming at giving a new impetus to this therapeutic field.

PMID:
31859623
DOI:
10.1051/medsci/2019188

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center